Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05468060
Other study ID # PA1010-101
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date June 28, 2020
Est. completion date December 12, 2020

Study information

Verified date July 2022
Source Zhejiang Palo Alto Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objectives of this study are to evaluate the safety, tolerability and pharmacokinetics characteristics of single ascending dose (SAD) of PA1010 tablets in Chinese healthy adults and the impact of food and gender on the pharmacokinetics


Description:

Stage I: Single dose, Single Ascending Dose (SAD) This is a randomized, double-blind, placebo-controlled, dose-escalation clinical trial. The objective is to evaluate the safety, tolerability and pharmacokinetics characteristics of PA1010 tablets in Chinese healthy subjects. There are six dose groups of PA1010 ( 5 mg、10 mg、20 mg、30 mg、45 mg and 60 mg) proposed to be tested sequentially in this study. A total of 60 healthy subjects are planned to be enrolled in this study and will be randomly assigned to the corresponding dose group in equal proportion, stratified by gender (male vs female). 10 subjects in each dose group are randomly assigned in a ratio of 4:1 to receive PA1010 tablets or placebo. All subjects will be dosed in a single dose, and the dose-related safety, tolerability and PK of PA1010 will be evaluated. Stage II: Study on the effect of food on Pharmacokinetics This is a single center, randomized, open, two group crossover, self-control clinical trial. A total of 20 subjects are planned to be enrolled in this study, and will be randomly assigned to a dosing order (i.e. fasting administration followed by high-fat meal administration, or high-fat meal administration followed by fasting administration) in a ratio of 1:1. Subjects will be dosed 10 mg PA1010 tablets in a single dose, and the food-related PK of PA1010 will be evaluated.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date December 12, 2020
Est. primary completion date December 12, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Male or female subjects aged between 18 and 55 (including upper and lower limits); 2. Body mass index (BMI) is between 18 and 28 kg/m2 (including upper and lower limits); 3. During the study period (from signing the informed consent to the last follow-up) and within 90 days after the last dose, there is no possibility of pregnancy (or making the sexual partner pregnant), childbirth or lactation, including: 1. Menopausal women who have menopause for more than 12 months or undergo sterilization (such as hysterectomy or bilateral ovariectomy); 2. Postmenopausal women, who have negative urine pregnancy test within 24 hours before the first dose, are willing to take more than one effective contraceptive method from the screening period to 90 days after the last dose, including intrauterine device, fallopian tube ligation, double barrier method (condom / vaginal diaphragm + spermicide) and male partner vas deferens ligation, but do not include oral contraceptives; 3. Men are willing to take more than one effective contraceptive method from the first dose to 90 days after the last dose, including vasectomy, double barrier method, female partner's use of contraceptives, intrauterine device or tubal ligation, etc.; 4. Avoid sex during the study period to 90 days after the last dose; 4. There is no history of major diseases, and the physical examination, vital signs, electrocardiogram and laboratory examination results during the screening period are normal, or although they exceed the normal reference value range, they are judged by the researcher to be of no clinical significance; 5. Be able to communicate with clinical staff normally and comply with the requirements of this study; 6. Sign the informed consent form to indicate willingness to participate in this study. Exclusion Criteria: 1. Any medical condition that the investigator considers to be likely to increase the risk of study participation (in particular, a history of esophageal or gastrointestinal ulcers), that may interfere with drug absorption, distribution, metabolism, or excretion, or that may impair adherence to the study protocol; 2. Those who have received any other study drug within 90 days before the first dose of the study drug; 3. Those who have received other prescription or over-the-counter drugs that will effect the study evaluation considered by the investigator that within 14 days prior to the first administration of the study drug (or within 5 half-lives of the drug, whichever is longer); 4. Those who have donated blood or lost a lot of blood (>400 ml) within 3 months before the first dose of the study drug; 5. Major surgery or great trauma within 6 months before the first dose of the study drug (the investigator make the judgement based on the previous medical history); 6. Consumption of beverages or foods containing grapefruit, pomegranate, papaya, grapes, carambola within 14 days, or do not agree to refrain from taking those beverages or foods every day during the study; 7. Any alcoholic products within 48 hours before the first administration of the study drug, or disagree to refrain from taking any alcohol products every day during the study; 8. Any foods or beverages rich in caffeine and xanthine within 48 hours before the first dose of the study drug(coffee, tea, coke, chocolate, seafood, animal liver, etc.) or disagree to refrain from taking those foods and beverages every day during the study; 9. Abnormal ECG during screening or baseline period, which is judged to be clinically significant by the investigator; Or QTcF > 450 ms during screening or baseline period; 10. History of heart disease, including a family history of sudden death caused by cardiac causes or QT interval prolongation syndrome; 11. History of serious kidney disease (judged by the investigator); 12. Difficulty in venous blood collection, or known to have a history of needle fainting and blood fainting for many times; 13. Clinical or laboratory evidence shows that there is one of the following situations: hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), syphilis carrying / infection; 14. Any history of food and drug allergy of clinical significance judged by the investigator; 15. Any history of drug abuse or urine drug test (+) in the screening period within 1 year before the first administration of the study drug; 16. Regular drinking history within 6 months before screening. Women have more than 7 cups / week, men have more than 14 cups / week (1 cup =5 ounces of wine or 12 ounces of beer or 1.5 ounces of spirits) or the alcohol test exceeds the standard during the screening period; 17. Those who cannot quit smoking as required during the study period or whose cigarette test paper (urine nicotine test) is positive during the screening period; 18. Participated in this study before.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PA1010
Placebo as control

Locations

Country Name City State
China Affiliated Hospital of Xuzhou Medical University Xuzhou Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Zhejiang Palo Alto Pharmaceuticals, Inc.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of subjects having abnormal hematology laboratory parameters Absolute and relative number of subjects with values below, within or above the normal range will be assessed. Up to 72 hours after last dose
Primary Number of subjects with abnormal clinical chemistry parameters Absolute and relative number of subjects with values below, within or above the normal range will be assessed. Up to 72 hours after last dose
Primary Number of subjects with abnormal values for urinalysis Absolute and relative number of subjects with values below, within or above the normal range will be assessed. Up to 72 hours after last dose
Primary Number of subjects with abnormal with blood coagulation function Absolute and relative number of subjects with values below, within or above the normal range will be assessed. Up to 72 hours after last dose
Primary Ear temperature Vital sign-ear temperature Up to 72 hours after last dose
Primary Systolic and diastolic blood pressure Vital sign-Systolic and diastolic blood pressure Up to 72 hours after last dose
Primary Pulse rate Vital sign-Pulse rate Up to 72 hours after last dose
Primary Breathing rate Vital sign-Breathing rate Up to 72 hours after last dose
Primary ECG parameter-QTc interval A 12 lead electrocardiogram (ECG) will be recorded using an ECG machine that automatically calculates the QTc intervals Up to 72 hours after last dose
Primary ECG parameter-PR interval A 12 lead electrocardiogram (ECG) will be recorded using an ECG machine that automatically measures PR intervals Up to 72 hours after last dose
Primary ECG parameter-QRS duration A 12 lead electrocardiogram (ECG) will be recorded using an ECG machine that automatically measures QRS duration Up to 72 hours after last dose
Primary Number of subjects experiencing adverse events (AEs) An adverse event (AE) is defined as any untoward medical occurrence in a clinical study subject administered a medicinal product which does not necessarily have a causal relationship with this treatment. Up to 4days after the last dose
Primary Pharmacokinetics of single dose of PA1010-Cmax Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Maximum Observed Plasma Concentration (Cmax) Up to 72 hours after last dose
Primary Pharmacokinetics of single dose of PA1010-Tmax Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Time to Reach Maximum Observed Plasma Concentration (Tmax) Up to 72 hours after last dose
Primary Pharmacokinetics of single dose of PA1010-AUC Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Area Under the Plasma Concentration-Time Curve (AUC) Up to 72 hours after last dose
Secondary Pharmacokinetics of single dose of PA1010-T1/2 Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Elimination Half-Life Period (T1/2) Up to 72 hours after last dose
Secondary Pharmacokinetics of single dose of PA1010-Vz/F Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Apparent Volume of Distribution(Vz/F) Up to 72 hours after last dose
Secondary Pharmacokinetics of single dose of PA1010-?z Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Elimination Rate Constant(?z) Up to 72 hours after last dose
Secondary Pharmacokinetics of single dose of PA1010-CL/F Blood samples will be collected serially, and the concentrations of PA1010 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Apparent Clearance(CL/F) Up to 72 hours after last dose
See also
  Status Clinical Trial Phase
Completed NCT04470388 - A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment Phase 1
Completed NCT05019040 - Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients Phase 1/Phase 2
Completed NCT01943799 - Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B Phase 2
Recruiting NCT05792761 - A Study on Antiviral Treatment of Chronic Hepatitis B in Children N/A
Completed NCT04008004 - A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2) Phase 1
Active, not recruiting NCT05734807 - A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia Phase 2
Completed NCT06029634 - Effects of T-bet B Cells in Persistent Virus Control After Discontinuance of NAs in CHB Patients
Completed NCT04147208 - Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection Phase 2
Completed NCT03909191 - Serum HBV RNA Value on Chronic Hepatitis B Virus Infection Manage
Completed NCT03664518 - to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection Phase 2
Completed NCT05542979 - A Study to Evaluate the Safety, Tolerability of HH-003 Injection in Participants With Chronic Hepatitis B Virus Infection Phase 1
Active, not recruiting NCT03903796 - Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection Phase 3
Completed NCT05851261 - Study to Evaluate the Safety, Tolerance, Pharmacokinetics Characteristics of PA3670 Tablets in Chinese Healthy Subjects Phase 1